U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07105488) titled 'A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis' on July 21.
Brief Summary: This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
BIOLOGICAL: BFB759
BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis
DRUG: Placeb...